OTCMKTS:BSTG Biostage (BSTG) Stock Price, News & Analysis $4.45 0.00 (0.00%) As of 07/24/2023 Add Compare Share Share Stock Analysis Stock Analysis About Biostage Stock (OTCMKTS:BSTG) Get Biostage alerts:Sign Up Key Stats Today's Range$4.45▼$4.4550-Day Range$4.45▼$4.4552-Week Range$4.45▼$4.45VolumeN/AAverage Volume1,847 shsMarket Capitalization$61.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Biostage, Inc. is a biotechnology company focused on regenerative medicine and the development of bioengineered organs and tissue-replacement products. Its approach is designed to use a patient’s own cells in combination with a biologic scaffold to create implantable tissue, with the goal of supporting reconstruction while reducing the risk of immune rejection. The company’s primary development program has centered on an engineered esophageal implant intended for patients who require esophageal reconstruction, including individuals affected by cancer, severe injury, or congenital conditions. Biostage has described its technology as the Cellframe platform, which was developed to support the growth of living tissue around a scaffold after implantation. Publicly available information about Biostage’s current operations, commercial products, geographic markets, and leadership is limited. The company has historically operated as a development-stage biotechnology business, and its programs have primarily been associated with precommercial research and clinical development rather than marketed products.AI Generated. May Contain Errors. Read More Receive BSTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biostage and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BSTG Stock News HeadlinesBiostage stock initiated with Buy rating at TD Cowen on specialty growthJune 24, 2025 | investing.comJefferies maintains Buy on Biostage shares with raised target amid bullish growth outlookJanuary 22, 2025 | msn.comElon Musk… A Total Fraud?Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, just got inside Elon Musk's new Cybercab, a vehicle with no steering wheel or pedals. In 2018, the New York Post called Musk a total fraud. Brown's latest footage shows just how far that technology has come since then.October 27 at 1:00 AM | Brownstone Research (Ad)Harvard Apparatus Regenerative Technology Inc (HRGN)January 5, 2024 | investing.comHRGN Harvard Apparatus Regenerative Technology Inc.August 22, 2023 | seekingalpha.comBiostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)July 20, 2023 | finance.yahoo.comBiostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal DiseaseJuly 18, 2023 | finance.yahoo.comBiostage CEO Awarded $1.07M Worth of Stock OptionsJuly 11, 2023 | benzinga.comSee More Headlines BSTG Stock Analysis - Frequently Asked Questions How have BSTG shares performed this year? Biostage's stock was trading at $4.45 at the beginning of the year. Since then, BSTG shares have increased by 0.0% and is now trading at $4.45. How were Biostage's earnings last quarter? Biostage, Inc. (OTCMKTS:BSTG) released its quarterly earnings data on Thursday, August, 13th. The company reported ($0.14) earnings per share for the quarter. Company Calendar Last Earnings8/13/2020Today10/27/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:BSTG CIK1563665 Webwww.biostage.com Phone(744) 233-7300Fax774-233-7302Employees7Year Founded2012Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.07 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-174.43% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-17.12Miscellaneous Outstanding Shares13,882,000Free Float11,758,000Market Cap$61.77 million OptionableNot Optionable Beta-1.02 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:BSTG) was last updated on 7/24/2023 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biostage, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biostage With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
